Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
35 hedge funds and large institutions have $897K invested in Statera Biopharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 6 closing their positions.
34% more capital invested
Capital invested by funds: $671K → $897K (+$226K)
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 33 → 35 (+2)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$379K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$39.3K |
| 3 |
BlackRock
New York
|
+$14.7K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.8K |
| 5 |
Jane Street
New York
|
+$6.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$105K |
| 2 |
VF
Virtu Financial
New York
|
-$50K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$28.5K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$22K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$17.2K |
STAB Hedge Fund Activity: Q2 2022 in Review
35 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2022, worth a combined $897K — up 34% from $671K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new STAB positions and 6 closed out — a net gain of 2 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $379K. The largest seller was Empery Asset Management, exiting entirely with an estimated $105K sold.
- 35 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2022, up from 33 in Q1 2022.
- Funds reported $897K of Statera Biopharma, Inc. Common Stock stock for Q2 2022, up 34% quarter-over-quarter.
- 8 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2022 and 6 closed out, a net change of +2 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2022 was Renaissance Technologies, an estimated $379K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2022 was Empery Asset Management, an estimated $105K sold.
Based on aggregated 13F filings for Q2 2022.